<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044520</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0535</org_study_id>
    <nct_id>NCT05044520</nct_id>
  </id_info>
  <brief_title>Clinical Features Associated With Restless Legs Syndrome.</brief_title>
  <acronym>Clin-RLS</acronym>
  <official_title>Clinical Features Associated With Restless Legs Syndrome : Clin-RLS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Restless legs syndrome (RLS) is a chronic neurological disorder characterized by an urge to&#xD;
      move the legs at night when at rest. RLS can lead to a sleep deprivation, increased falling&#xD;
      risk, daytime sleepiness, depression and decreased quality of life. Dopamine agonists,&#xD;
      alpha-2-delta ligands and opiates are key medications for RLS. The natural course of RLS is&#xD;
      very heterogeneous with a risk of increasing the severity of symptoms over the years despite&#xD;
      the use of drugs and recommended dosages. Many comorbidities can make RLS worse. Augmentation&#xD;
      syndrome is the main complication of dopamine agonists. However, only a few studies have&#xD;
      addressed the clinical, biological and pharmacological factors associated with the evolution&#xD;
      of the severity of RLS. The objective of this study is to assess the evolution of RLS&#xD;
      symptoms severity as function of RLS phenotype, comorbidities and RLS medication, in large&#xD;
      cohort of members of the French RLS association and other European RLS association.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators want to study the clinical course of RLS in a population of&#xD;
      RLS patients who are members of the RLS patient association, taking into account clinical and&#xD;
      biological factors as well as the treatments taken for RLS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>International restless legs syndrome study group rating scale (IRLS)</measure>
    <time_frame>Four minutes</time_frame>
    <description>International restless legs syndrome study group rating scale (IRLS). ranging from 0 to 40, with higher scores indicating worse restless legs symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restless Legs Syndrome-6 Scale (RLS-6)</measure>
    <time_frame>two minutes</time_frame>
    <description>Restless Legs Syndrome-6 Scale (RLS-6)symptoms after a surgical procedure under general or locoregional anesthesia. ranging from 0 to 60, with higher scores indicating worse restless legs symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Severity Rating Scale (ASRS)</measure>
    <time_frame>two minutes</time_frame>
    <description>Augmentation Severity Rating Scale (ASRS). ranging from 0 to 24, with higher scores indicating worse augmentation symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth severity scale (ESS)</measure>
    <time_frame>two minutes</time_frame>
    <description>Epworth severity scale (ESS). ranging from 0 to 24, with higher scores indicating worse sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>two minutes</time_frame>
    <description>Insomnia Severity Index (ISI). ranging from 0 to 28, with higher scores indicating worse insomnia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory - II (BDI-II)</measure>
    <time_frame>Six minute</time_frame>
    <description>Beck's Depression Inventory - II (BDI-II). ranging from 0 to 63, with higher scores indicating worse depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of life - 5 dimensions (EQ-5D)</measure>
    <time_frame>One minute</time_frame>
    <description>European Quality of life - 5 dimensions (EQ-5D). ranging from 0 to 100. Higher scores indicate better health condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homemade questionnaire assessing the falling risk</measure>
    <time_frame>Five minutes</time_frame>
    <description>Homemade questionnaire assessing the falling risk. ranging from 0 to 6, with higher scores indicating worse falling risk</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with RLS who are members of the RLS patient association&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adults subjects&#xD;
&#xD;
          -  Restless legs syndrome diagnosis&#xD;
&#xD;
          -  Member of the restless legs syndrome association&#xD;
&#xD;
          -  French speaking&#xD;
&#xD;
          -  Able to understand the study&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Affiliated to social security&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Vulnerable subject : subject deprived of liberty or protected by law (trusteeship, legal&#xD;
        guardianship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves DAUVILLIERS, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofiene Chenini, MD</last_name>
    <phone>467332237</phone>
    <phone_ext>33</phone_ext>
    <email>sofienechenini@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yves DAUVILLIERS, MD PhD</last_name>
    <phone>467337478</phone>
    <phone_ext>33</phone_ext>
    <email>y-dauvilliers@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofiene Chenini, MD</last_name>
      <phone>467332237</phone>
      <phone_ext>33</phone_ext>
      <email>sofienechenini@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yves DAUVILLIERS, MD PhD</last_name>
      <phone>467337478</phone>
      <phone_ext>33</phone_ext>
      <email>y-dauvilliers@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restless legs syndrome</keyword>
  <keyword>Augmentation syndrome</keyword>
  <keyword>Dopamine agonists</keyword>
  <keyword>Alpha 2 delta ligands</keyword>
  <keyword>Opiates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

